On January 13, Tsinghua University signed an agreement for a new drug development project with Beijing Jialin Pharmaceutical Co., Ltd. Dr. SHI Yigong, Vice-President of Tsinghua University and LIU Wei, President of Beijing Jialin Pharmaceutical Co.,Ltd witnessed the signing. The collaboration aims to develop new cancer drugs.
SHI highlighted the rapid development in the past decade for life science, medicine and pharmaceutical sciences at Tsinghua University, which has been driven by the University’s support, government funding and now the investment form the industry.
LIU pointed out that Jialin has been focusing on new drug development for cardiovascular diseases and cancers. The collaboration with Tsinghua will further enhance its R&D capabilities and drive the sustainable growth of the company.
Recently, Dr. HE Wei reached a significant technology transfer agreement with Beijing Jialin Pharmaceutical Co., Ltd. under favorable terms. This "BRM Inhibition Based New Cancer Drug Development Technology" will be further developed at the company for new drug discovery.
